Xtant Medical Holdings, Inc. 8K

Xtant Medical Holdings, Inc. reported weaker Q1 2026 results but reduced debt, completed its Companion Spine asset-sale proceeds, entered an exclusive U.S. HEMOBLAST Bellows distribution deal with Dilon Technologies while hiring Dilon’s U.S. sales team, launched a new Trivium Shaped product, and raised full-year 2026 revenue guidance to $101–$105 million.

On May 13, 2026, Xtant Medical Holdings, Inc. reported its financial and operating results for the quarter ended March 31, 2026, highlighting a sharp year-over-year revenue decline to $20.9 million primarily due to the December 2025 sale of Coflex/CoFix assets and its international hardware business to Companion Spine and the non-recurrence of 2025 license revenue, alongside a swing from a small net profit in Q1 2025 to a $3.1 million net loss and a negative adjusted EBITDA of $1.6 million. The company significantly strengthened its balance sheet by reducing total indebtedness by $13.3 million, including substantial paydowns on its revolving credit facility and term loan funded in part by the final $10.7 million received from Companion Spine in March 2026, leaving cash and cash equivalents of $12.2 million and total debt of $12.2 million as of March 31, 2026. Operationally, Xtant entered into an exclusive U.S. distribution agreement with privately held Dilon Technologies for the HEMOBLAST Bellows hemostatic product and hired Dilon’s approximately 20-person U.S. sales team (referenced elsewhere as a 21-person field force), expanding its presence in the hemostasis market, and launched Trivium Shaped, an extension of its premium demineralized bone matrix allograft line. Reflecting anticipated incremental revenue from the HEMOBLAST Bellows license announced in April 2026 and the expanded sales force, the company raised its full-year 2026 revenue guidance from $95–$99 million to $101–$105 million and scheduled a same-day webcast and conference call for investors to review its results and outlook.

Filing Facts

CIK

1453593

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-022600

Alert Tier

7